Bodyweight gain with atypical antipsychotics: A comparative review

Drug Safety

Volumn 24, Issue 1, 2001, Pages 59-73

  Wetterling, T ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOBESITY AGENT; CLOZAPINE; DOPAMINE 2 RECEPTOR; FENFLURAMINE; HISTAMINE H1 RECEPTOR; LEPTIN; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; ZIPRASIDONE; ZOTEPINE;

CLINICAL TRIAL; DOSE RESPONSE; DRUG MECHANISM; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; HUMAN TISSUE; LONG TERM CARE; MAJOR CLINICAL STUDY; META ANALYSIS; OBESITY; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SCHIZOPHRENIA; WEIGHT GAIN;

EID: 0035153224     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200124010-00005     Document Type: Review

References (93)

1. What makes an antipsychotic 'atypical'?
2. Selecting an atypical antipsychotic by combining clinical experience with guidelines from clinical trials
3. Mechanisms of action of atypical antipsychotic drugs: A critical analysis
4. Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding
5. Do novel antipsychotics have similar pharmacological characteristics
6. Antipsychotic-induced weight gain: A comprehensive research synthesis
7. Induction of obesity by psychotropic drugs
8. Weight gain associated with neuroleptic medication: A review
9. Weight gain: Side effect of atypical neuroleptics?
10. Novel antipsychotics: Comparison of weight gain liabilities
11. The distribution of Body Mass Index among individuals with and without schizophrenia
12. Weight gain among schizophrenic patients treated with clozapine
13. Prevalence of obesity in patients receiving depot antipsychotics
14. Body weight and leptin plasma levels during treatment with antipsychotic drugs
15. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: A randomized double-blind study
16. Differential effect of clozapine on weight: A controlled study
17. Assessment of changes in both weight and frequency of use of medications for the treatment of gastrointestinal symptoms among clozapine-treated patients
18. Clozapine-induced weight gain: Prevalence and clinical relevance
19. Weight changes during clozapine treatment
20. Weight gain induced by clozapine
21. Clozapine et schizophrenies resistantes
22. The effect of long-term antipsychotic treatment on the body weight of patients suffering from chronic schizophrenia: Clozapine versus classical antipsychotic agents
23. Clozapine in the treatment of 121 out-patients
24. Tolerability and therapeutic effect of clozapine
25. Olanzapine versus placebo in the treatment of acute mania
26. Olanzapine versus placebo: Results of a double-blind, fixed-dose olanzapine trial
27. Olanzapine versus haloperidol in the treatment of schizophrenia and schzoaffectire and schizophreniform disorders: Results of an international collaborative trial
28. Olanzapine versus haloperidol in the treatment of schizoaffective disorder
29. Risperidone versus olanzapine in patients with schizophrenic and schizoaffective psychosis
30. Olanzapine increases weight and serum triglyceride levels
31. Olanzapine in treatment-resistant bipolar disorder
32. Olanzapine: Weight gain and therapeutic efficacy
33. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders
34. Safety of olanzapine
35. USS ICI 204,636, an atypical antipsychotic: Efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia
36. A comparison of quetiapine (ICI 204,636, 'Seroquel') and haloperidol in schizophrenia
37. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia
38. Multiple fixed doses of 'Seroquel' (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo
39. Quetiapine in patients with schizophrenia
40. A comparison of bd and tid dose regimens of quetiapine (Seroquel) in the treatment of schizophrenia
41. A comparison of the effects of quetiapine ('Seroquel') and haloperidol in schizophrenic patients with a history of and a demostrated, partial response to conventional antipsychotic treatment
42. Risperidone in the treatment of patients with chronic schizophrenia: A multi-national, multi-centre, double-blind, parallel-group study versus haloperidol
43. Risperidone, a novel antipsychotic, and weight change
44. Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations
45. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: A multicentre double-blind comparative study
46. Clinical and economic aspects of risperidone treatment in adults with mental retardation and behavioral disturbance
47. Risperidone vs. haloperidol as relapse prevention in schizophrenic and schizoaffectire disorders
48. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 6-week placebo-controlled trial
49. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrernia and schizoaffective disorder: A 4-week placebo-controlled trial
50. A comparison of an atypical and typical antipsychotic, zotepine versus haloperidol in patients with acute exacerbation of schizophrenia: A parallel-group double-blind trial
51. Weight gain associated with clozapine
52. Clozapine (Leponex) overdosage
53. Clozapine and weight gain
54. Olanzapine versus placebo and haloperidol
55. Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: An open-label pilot study
56. Open-label quetiapine in the treatment of children and adolescents with autistic disorder
57. Risperidone and explosive aggressive autism
58. An open clinical trial of risperidone monotherapy in young children with autistic disorder
59. Risperidone treatment of children and adolescents with chronic tic disorders: A preliminary report
60. Weight gain in adolescents treated with risperidone and conventional antipsychotics over six months
61. Risperidone treatment of children and adolescents with pervasive developmental disorders: A prospective open-label study
62. Risperidone-induced hepatotoxicity in children and adolescents? A chart review study
63. Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses
64. Risperidone versus zuclopenthixol in the treatment of acute schizophrenic episodes: A double-blind parallel group trial
65. Randomized, double-blind, controlled trial of risperidone versus clozapine in patients with chronic schizophrenia
66. Risperidone in the treatment of schizophrenia: A meta-analysis of randomized controlled trials
67. Gewichtszunahme- eine Nebenwirkung von Nipolept (Zotepin)?
68. Too many chronic mentally disabled patients are too fat
69. D2 and 5-HT2 receptor effects of antipsychotics: Bridging basic and clinical findings using PET
70. Serotonin and appetite
71. The role of serotonin in eating disorders
72. Carbohydrate craving in obese people: Suppression by treatments affecting serotoninergic transmission
73. Fluoxetine's effect on weight loss in obese subjects
74. Biochemical pharmacology of the anorectic drug fenfluramine: A review
75. 2 receptors in the food intake suppressant effects of 1-(2,5-dimethoxy-iodophenyl)-2-amidopropane (DOI)
76. 2c serotonin receptors
77. Clozapine and associated diabetes mellitus
78. Novel antipsychotics and new onset diabetes
79. Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychoses
80. Prevalence of diabetes and impaired glucose tolerance in patients treated with conventional depot neuroleptic medications
81. Serum leptin levels increase rapidly after initiation of clozapine therapy
82. Prevalence of smoking among psychiatric outpatients
83. Effects of clozapine on smoking in chronic schizophrenic outpatients
84. Clozapine decreases smoking in patients with chronic schizophrenia
85. Weight gain as a predictor of long term clozapine efficiency
86. The efficacy and safety of clozapine versus chlorpromazine in geriatric schizophrenia
87. Body weight gain induced by antipsychotic drugs: Mechanisms and management
88. Clinical trial of the efficacy and acceptability of D-fenfluramine in the treatment of neuroleptic-induced obesity
89. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults - The evidence report
90. Weight, weight change, and coronary heart disease in women: Risk within the 'normal' weight range
91. Determinants of medication compliance in schizophrenia: Empirical and clinical findings
92. Clinically significant side-effects of lithium treatment. A survey of 237 patients in long-term treatment
93. Towards the improvement of compliance: The significance of psycho-eduction and new antipsychotic drugs